BR0307906A - Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2 - Google Patents
Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2Info
- Publication number
- BR0307906A BR0307906A BR0307906-6A BR0307906A BR0307906A BR 0307906 A BR0307906 A BR 0307906A BR 0307906 A BR0307906 A BR 0307906A BR 0307906 A BR0307906 A BR 0307906A
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- inhibitor
- combinations
- delta
- selective cyclooxygenase
- Prior art date
Links
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 4
- 239000003446 ligand Substances 0.000 title abstract 3
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- 229940111134 coxibs Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229960002004 valdecoxib Drugs 0.000 abstract 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 abstract 2
- -1 1-aminomethylcyclohexylmethyl Chemical group 0.000 abstract 1
- BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical compound O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 abstract 1
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 abstract 1
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 229960000590 celecoxib Drugs 0.000 abstract 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
- 229960000371 rofecoxib Drugs 0.000 abstract 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35929502P | 2002-02-22 | 2002-02-22 | |
| US40436502P | 2002-08-19 | 2002-08-19 | |
| PCT/IB2003/000534 WO2003070237A1 (en) | 2002-02-22 | 2003-02-12 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0307906A true BR0307906A (pt) | 2004-12-21 |
Family
ID=27760521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0307906-6A BR0307906A (pt) | 2002-02-22 | 2003-02-12 | Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20030199567A1 (https=) |
| EP (1) | EP1480639A1 (https=) |
| JP (1) | JP2005523281A (https=) |
| KR (1) | KR20040085216A (https=) |
| CN (1) | CN1635887A (https=) |
| AR (1) | AR038531A1 (https=) |
| AU (1) | AU2003246864A1 (https=) |
| BR (1) | BR0307906A (https=) |
| CA (1) | CA2476438A1 (https=) |
| CO (1) | CO5611109A2 (https=) |
| HN (1) | HN2003000071A (https=) |
| IL (1) | IL162932A0 (https=) |
| MX (1) | MXPA04008175A (https=) |
| NO (1) | NO20043947L (https=) |
| PA (1) | PA8567201A1 (https=) |
| PE (1) | PE20031052A1 (https=) |
| PL (1) | PL372210A1 (https=) |
| RU (1) | RU2286151C2 (https=) |
| TW (1) | TW200303214A (https=) |
| UY (1) | UY27675A1 (https=) |
| WO (1) | WO2003070237A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003303041B2 (en) * | 2002-12-13 | 2008-07-24 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
| AU2004224322A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| WO2004084881A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
| US20060264509A1 (en) * | 2003-03-21 | 2006-11-23 | Fraser Matthew O | Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators |
| US7169812B2 (en) | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
| AU2004271800A1 (en) * | 2003-09-12 | 2005-03-24 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| WO2005041976A2 (en) * | 2003-10-23 | 2005-05-12 | Medtronic, Inc. | Injectable gabapentin compositions |
| JP2009533368A (ja) * | 2006-04-11 | 2009-09-17 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| US20130012485A1 (en) * | 2006-12-22 | 2013-01-10 | Baeschlin Daniel Kaspar | Organic compounds |
| US20090275529A1 (en) * | 2008-05-05 | 2009-11-05 | Reiss Allison B | Method for improving cardiovascular risk profile of cox inhibitors |
| KR101730924B1 (ko) * | 2008-09-05 | 2017-04-27 | 그뤼넨탈 게엠베하 | 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물 |
| KR102631399B1 (ko) * | 2018-03-30 | 2024-02-01 | 씨지인바이츠 주식회사 | 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물 |
| CA3200132A1 (en) * | 2020-10-28 | 2022-05-05 | Tremeau Pharmaceuticals, Inc. | Aqueous formulations of water insoluble cox-2 inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234929A (en) * | 1992-07-20 | 1993-08-10 | William Chelen | Method of treating motion sickness with anticonvulsants and antitussive agents |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5420270A (en) * | 1993-10-07 | 1995-05-30 | G. D. Searle & Co. | Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use |
| US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5352638A (en) * | 1994-02-22 | 1994-10-04 | Corning Incorporated | Nickel aluminosilicate glass-ceramics |
| AU703428B2 (en) * | 1994-07-27 | 1999-03-25 | Warner-Lambert Company | Use of gabapentin in the treatment of anxiety and panic |
| US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| WO1999008670A1 (en) * | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| JP3782935B2 (ja) * | 1997-09-08 | 2006-06-07 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法 |
| NZ503980A (en) * | 1997-12-16 | 2002-09-27 | Warner Lambert Co | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (= gabapentin analogues), pharmaceuticals thereof, and their use in the treatment of neurological disorders |
| US6451857B1 (en) * | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| PL351069A1 (en) * | 1999-12-08 | 2003-03-10 | Pharmacia Corp | Valdecoxib compositions |
-
2003
- 2003-02-12 PL PL03372210A patent/PL372210A1/xx not_active Application Discontinuation
- 2003-02-12 AU AU2003246864A patent/AU2003246864A1/en not_active Abandoned
- 2003-02-12 RU RU2004125609/15A patent/RU2286151C2/ru not_active IP Right Cessation
- 2003-02-12 IL IL16293203A patent/IL162932A0/xx unknown
- 2003-02-12 KR KR10-2004-7013032A patent/KR20040085216A/ko not_active Ceased
- 2003-02-12 EP EP03742460A patent/EP1480639A1/en not_active Withdrawn
- 2003-02-12 JP JP2003569193A patent/JP2005523281A/ja not_active Abandoned
- 2003-02-12 CA CA002476438A patent/CA2476438A1/en not_active Abandoned
- 2003-02-12 BR BR0307906-6A patent/BR0307906A/pt not_active IP Right Cessation
- 2003-02-12 WO PCT/IB2003/000534 patent/WO2003070237A1/en not_active Ceased
- 2003-02-12 MX MXPA04008175A patent/MXPA04008175A/es unknown
- 2003-02-12 CN CNA038043564A patent/CN1635887A/zh active Pending
- 2003-02-14 US US10/366,798 patent/US20030199567A1/en not_active Abandoned
- 2003-02-17 PE PE2003000166A patent/PE20031052A1/es not_active Application Discontinuation
- 2003-02-19 UY UY27675A patent/UY27675A1/es not_active Application Discontinuation
- 2003-02-20 AR ARP030100547A patent/AR038531A1/es unknown
- 2003-02-21 HN HN2003000071A patent/HN2003000071A/es unknown
- 2003-02-21 TW TW092103596A patent/TW200303214A/zh unknown
- 2003-02-21 PA PA20038567201A patent/PA8567201A1/es unknown
-
2004
- 2004-08-13 CO CO04079024A patent/CO5611109A2/es not_active Application Discontinuation
- 2004-09-21 NO NO20043947A patent/NO20043947L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8567201A1 (es) | 2003-11-12 |
| CO5611109A2 (es) | 2006-02-28 |
| RU2004125609A (ru) | 2006-01-27 |
| AR038531A1 (es) | 2005-01-19 |
| CN1635887A (zh) | 2005-07-06 |
| TW200303214A (en) | 2003-09-01 |
| PE20031052A1 (es) | 2003-12-24 |
| WO2003070237A1 (en) | 2003-08-28 |
| PL372210A1 (en) | 2005-07-11 |
| IL162932A0 (en) | 2005-11-20 |
| RU2286151C2 (ru) | 2006-10-27 |
| MXPA04008175A (es) | 2004-11-26 |
| EP1480639A1 (en) | 2004-12-01 |
| NO20043947L (no) | 2004-09-21 |
| UY27675A1 (es) | 2003-09-30 |
| HN2003000071A (es) | 2003-11-24 |
| CA2476438A1 (en) | 2003-08-28 |
| KR20040085216A (ko) | 2004-10-07 |
| AU2003246864A1 (en) | 2003-09-09 |
| JP2005523281A (ja) | 2005-08-04 |
| US20030199567A1 (en) | 2003-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0307906A (pt) | Combinações de um ligando alfa-2-delta com um inibidor seletivo de ciclooxigenase-2 | |
| Li et al. | Citrullinated histone H3: a novel target for the treatment of sepsis | |
| AU2003301109A8 (en) | Pharmaceutical compositions and method of treating Parkinson's disease | |
| DK1443967T3 (da) | Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor | |
| ATE469674T1 (de) | 5-aminolävulinsäure-derivate zur behandlung von akne | |
| EA200401471A1 (ru) | Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов | |
| BRPI0418244A (pt) | composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica | |
| EA200100905A1 (ru) | Фармацевтическая композиция, содержащая ингибиторы протонного насоса | |
| WO2007131364A8 (en) | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties | |
| EP1627639A3 (en) | Use of COX-2 inhibitors for the treatment of affective disorders | |
| BRPI0720500A8 (pt) | Preparação líquida transdérmica | |
| ATE414526T1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
| CY1115516T1 (el) | Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα | |
| EA200500941A1 (ru) | Средство для лечения болезней суставов | |
| Eren et al. | Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids | |
| BRPI0415628A (pt) | suspensões analgésicas para liberação controlada | |
| Barzkar et al. | Jellyfish protein hydrolysates: Multifunctional bioactivities unveiled in the battle against diabetes, inflammation, and bacterial pathogenesis | |
| EP2286807A3 (en) | Medicament for preventive and/or therapeutic treatment of adhesion of bowel | |
| EA200300940A1 (ru) | Энтеральные соли кетокислот и аминокислот | |
| WO2004006931A3 (en) | Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 | |
| BRPI0415630A (pt) | suspensões analgésicas para liberação controlada | |
| BR0213633A (pt) | Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos | |
| EP1652525A4 (en) | ANTI-VIRUS CORONA DRUG | |
| BR0308118A (pt) | Método para o tratamento de osteoartrite | |
| BR0308156A (pt) | Composições farmacêuticas sólidas contendo lumiracoxib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 31/42; A61P 29/00 Ipc: A61K 31/42 (2011.01), A61P 29/00 (2011.01) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES. |